Monday 6-9-2014 Avanir Pharmaceuticals Inc (AVNR) $AVNR

New Post Public Reply Private Reply Replies (0) Message Board

Jun 9, 2014 at 5:42 PM

Monday 6-9-2014 Avanir Pharmaceuticals Inc (AVNR) $AVNR opened at 5.30 hitting the high price of 5.44 and a day low of 5.27 with a total volume of 1,925,166. AVNR had a previous close of 5.28 and has been seeing an average volume of 2,621,350.

Overall Average: 88% Buy

Recent stock forum discussions about AVNR http://investorshangout.com/search?q=AVNR&...mp;yt0=Go!

AVANIR Pharmaceuticals Has Returned 19.7% Since SmarTrend Recommendation (AVNR)
Comtex SmarTrend(R) - Wed Jun 04, 9:19AM CDT
SmarTrend identified an Uptrend for AVANIR Pharmaceuticals (NASDAQ:AVNR) on April 30th, 2014 at $4.21. In approximately 1 month, AVANIR Pharmaceuticals has returned 19.71% as of today's recent price of $5.04. (full story)

Ignyta (RXDX) Jumps: Stock Adds 12.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 7:51AM CDT
Ignyta, Inc. (RXDX) was a big mover last session, as its shares rose nearly 13% on the day. (full story)

Health Care Sector Equities Scrutiny -- Research on AVANIR Pharma, Zoetis, Actavis, and Mallinckrodt
PR Newswire - Tue Jun 03, 6:50AM CDT
On Monday, June 2, 2014, the NASDAQ Composite ended at 4,237.20, down 0.13%, the Dow Jones Industrial Average edged 0.16% higher to finish the day at 16,743.63, and the S&P 500 closed at 1,924.97, up 0.07%. During the session gains in the Materials, Industrials, and Consumer Discretionary sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Energy, and Information Technology sectors. The S&P 500 Health Care Sector Index ended the day at 691.40, up 0.17%, with the index advancing 3.37% in the last one month. Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT) and Mallinckrodt PLC (NYSE: MNK). Free technical research on AVNR, ZTS, ACT and MNK can be downloaded upon signing up at: (full story)

Patients Enrolled in Avanir Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 4:35PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) finished enrolling patients in a phase II label expansion study on AVP-923 for the treatment of agitation due to Alzheimer's disease. (full story)

Pipeline Update from Avanir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 4:00PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) finished enrolling patients in a phase II label expansion study on AVP-923 for the treatment of agitation due to Alzheimer's disease. (full story)

NPS Pharmaceuticals (NPSP) in Focus: Stock Rises 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 8:46AM CDT
NPS Pharmaceuticals (NPSP) was a big mover last session, with shares rising over 13% on the day. (full story)

Avanir Pharmaceuticals Announces Multiple Data Presentations Related to Pseudobulbar Affect (PBA) Prevalence and Treatment at Two Conferences in June
PR Newswire - Fri May 30, 8:00AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June. (full story)

Avanir Pharmaceuticals to Participate in Two Conferences in June
PR Newswire - Wed May 28, 8:00AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in June. (full story)

4 Stocks Under $10 in Breakout Territory
at The Street - Wed May 28, 6:49AM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)

Shares of AVNR Up 19.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue May 27, 5:19PM CDT
SmarTrend identified an Uptrend for AVANIR Pharmaceuticals (NASDAQ:AVNR) on April 30th, 2014 at $4.21. In approximately 4 weeks, AVANIR Pharmaceuticals has returned 19.71% as of today's recent price of $5.04. (full story)

Avanir Pharmaceuticals Announces Completion of Patient Enrollment in Study of AVP-923 for the Treatment of Agitation in Patients with Alzheimer's Disease
PR Newswire - Tue May 27, 8:00AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled study testing AVP-923 for the treatment of agitation in Alzheimer's disease patients. Top-line results from this study are expected late September/early October. (full story)

Biodel Q2 Loss Wider Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 9:20AM CDT
Biodel Inc.'s (BIOD) loss was wider-than-expected in the second quarter of fiscal 2014. (full story)

Avanir Pharmaceuticals (AVNR) in Focus: Stock Moves 6.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 15, 8:18AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares rise by over 6% on the day. (full story)

QLT Inc. (QLTI) Falls: Stock Goes Down 9.13% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 14, 8:00AM CDT
QLT Inc. (QLTI) saw a big move last session, as the company’s shares fell by over 9% on the day (full story)

Avanir Loss In Line with Ests, Revs Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:00PM CDT
Avanir Pharma (AVNR) reported second quarter fiscal 2014 net loss per share of 8 cents, in line with the Zacks Consensus Estimate. (full story)

Avanir's Loss Narrows as Nuedexta Revenue Rises
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 4:21PM CDT
Small-cap biopharmaceutical company Avanir Pharmaceuticals continued to showcase its progress to investors today by reporting greatly improved sales and a narrower loss with the release of its second-quarter results after the closing bell. For... (full story)

Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results
PR Newswire - Tue May 06, 3:01PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014. (full story)

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri May 02, 8:45AM CDT
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)

Upgrade Alert for AVANIR Pharmaceuticals (AVNR)
Comtex SmarTrend(R) - Fri May 02, 7:03AM CDT
AVANIR Pharmaceuticals (NASDAQ:AVNR) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $4.65 on volume of 11.7 million shares, above average daily volume of 2.0 million. AVANIR Pharmaceuticals Inc. develops, acquires, and markets treatments for central nervous system disorders, inflammation, and infectious diseases. (full story)

Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor. (full story)

Avanir Pharmaceuticals Inc (AVNR) Stock Research Links

AVNR Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Behavioral Crisis Center Saves Mobile $101M Since 2021

AltaPointe Saves Millions While Supporting Community Health Let's dig into this remarkable achievement by the AltaPointe Behavioral Health Crisis Center. Since opening its doors in May 2021, the Mobile, Alabama facility has notched up a mind-boggling $101.5 million in community savings. This isn’t merely about numbers on a ledger—it's about real human impact, better...

Immunic Pushes Boundaries in MS with Vidofludimus

Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...

Replay Sports Cards Expands to Greenville With New Franchise

An Old Hobby Gets New Life in Greenville Isn't it something when a hobby from your childhood eventually morphs into a business venture? That's exactly what's happening in Greenville, North Carolina, where Replay Sports Cards is laying down roots. Thanks to Jim and Jake Whitehurst's fresh franchise agreement, the card community along the eastern seaboard is about to have a...

Lindian's Bold Leap into Rare Earths Processing

Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...

Plan A Bets on AI in High-Stakes M&A Arena

Digging Deeper with AI in M&A Deals Picture this: you’re at the table with a fat corporate M&A deal, eyes darting as you decipher numbers and nods, when out swings Plan A Technologies with their new ace up their sleeve—a stealth AI assessment tool armed to sharpen their technical due diligence. Unmasking the Tech Jigsaw Las Vegas-based Plan A Technologies hasn't just...

BlueSky Enters Nashville: In-Home Vet Care Begins

Nashville Welcomes A New Wave of Pet Care In a world where convenience is king, BlueSky At-Home Veterinary Care is stepping up to the plate—or should I say, doorstep—by rolling out its fresh take on veterinary services in Nashville. Kicking off on September 15, 2026, this isn't just any ol' run-of-the-mill clinic opening. We're talking about vets coming straight to...

Nanochon Tests Innovative Knee Implant in Human Trial

Mending Knees with New Tech: The Chondrograft™ Debut Picture this: Nanochon's Chondrograft™ just hit the ground running. They've got a bite out of the future by diving headfirst into their First-in-Human (FIH) clinical study. This ain't your grandma's knee replacement talk. This is about changing the game for those knee cartilages that let out a groan every time you...

Herzog Joins Greenberg Traurig: A Litigation Powerhouse

Greenberg Traurig Welcomes David M. Herzog to the Team Ah, the rat race of litigation just got a bit fiercer with Greenberg Traurig's latest acquisition: David M. Herzog. This isn’t just another lawyer joining the ranks; Herzog's a dynamo, coming in hot from the U.S. Attorney's Office, right onto the battlefield of corporate litigation. Why Herzog's Move Matters...

Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Geron Faces Legal Woes: Investors Watch for Fallout

Legal Storm Brewing Around Geron Corporation Ah, the familiar smell of trouble in corporate paradise, and this time it's drifting from Geron Corporation (NASDAQ: GERN). If you've got your chips on the table with these guys, you'd better pony up and listen up. Kuehn Law, PLLC is lighting a fire under Geron's board, snooping on whether their head honchos scuttled their...